Merck Serono to grow Japanese business
Merck Serono, a division of Germany's Merck KGaA, says it will expand its Japanese business following the launch of Erbitux (cetuximab) before the end of 2008.
The drug was approved by the Japanese Ministry of Health, Labor and Welfare last month (Marketletter July 17) and is to be marketed in partnership with the local subsidiaries of USA-based ImClone Systems and Bristol-Myers Squibb.
Once Erbitux has been released, Merck chairman Karl-Ludwig Kley, says, the firm "aims to increase [total] Japanese sales about three times current levels, to 150.0 billion yen ($1.39 billion) in three to five years."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze